Showing results (51-60 of 2,117) with videos related to
Sort By:
Pageof 212
International Clinical Psychopharmacology|April 13, 2004
Huntington's disease: present treatments and future therapeutic modalitiesRaphael M Bonelli, Gregor K Wenning, Hans P KapfhammerInternational Clinical Psychopharmacology|April 13, 2004
Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scaleJonathan R T DavidsonInternational Clinical Psychopharmacology|April 13, 2004
Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of maniaLakshmi N Yatham, Carin Binder, Vivek Kusumakar, et al.International Clinical Psychopharmacology|April 7, 2005
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapiesHans-Jürgen Möller, Pierre-Michel Llorca, Emilio Sacchetti, et al.International Clinical Psychopharmacology|April 7, 2005
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphismMasaki Kato, Yuka Ikenaga, Masataka Wakeno, et al.International Clinical Psychopharmacology|April 7, 2005
Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatmentYong Min Ahn, Jae Seung Chang, Yeni Kim, et al.International Clinical Psychopharmacology|June 4, 2005
Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorderNatalie Ciliberto, Cynthia A Bossie, Ronald Urioste, et al.International Clinical Psychopharmacology|June 4, 2005
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placeboCharles Shelton, Richard Entsuah, S Krishna Padmanabhan, et al.International Clinical Psychopharmacology|August 13, 2005
Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation studyJay D Amsterdam, Justine ShultsInternational Clinical Psychopharmacology|March 11, 2006
Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipranChristian Puozzo, Philippe Hermann, Didier ChassardPageof 212